Randomized Controlled Trial of Carvedilol Versus Endoscopic Band Ligation for Primary Prophylaxis of Oesophageal Variceal Bleeding in Cirrhotic Patients With Arterial Hypertension

What this Trial Is About

This trial compares carvedilol, a medication, with endoscopic band ligation, a procedure, to prevent the first episode of bleeding from esophageal varices in patients who have liver cirrhosis and arterial hypertension. The study evaluates which method might better reduce the risk of variceal bleeding, a serious complication in these patients. It is a randomized controlled trial sponsored by Sherief Abd-Elsalam and includes adult participants aged 18 and older. Participants are randomly assigned to receive either carvedilol or undergo endoscopic band ligation. Carvedilol is given as a drug treatment, while endoscopic band ligation involves a procedure to tie off enlarged veins in the esophagus to prevent bleeding. The study monitors patients over a one-year period to compare the effects of these two approaches as primary prevention for variceal bleeding. During the study, participants will be assessed to see if they experience their first variceal bleeding within one year. Researchers will perform regular evaluations to monitor the patients' health and the condition of their esophageal varices. Safety and tolerability are also observed, with follow-up visits to track outcomes and any complications related to the treatments. The total participation time is at least one year based on the primary outcome measure.

Carvedilol Versus Endoscopic Band Ligation for Primary Prophylaxis of Oesophageal Variceal Bleeding